Publicaciones en las que colabora con Juan Berenguer Berenguer (18)

2024

  1. Plasma metabolomic profile is near-normal in people with HIV on long-term suppressive antiretroviral therapy

    Frontiers in Cellular and Infection Microbiology, Vol. 14

2023

  1. Corrigendum to “PBMCs gene expression signature of advanced cirrhosis with high risk for clinically significant portal hypertension in HIV/HCV coinfected patients: A cross-control study” [Biomed. Pharmacother. 159 (2023) 114220] (Biomedicine & Pharmacotherapy (2023) 159, (S0753332223000082), (10.1016/j.biopha.2023.114220))

    Biomedicine and Pharmacotherapy

  2. PBMCs gene expression signature of advanced cirrhosis with high risk for clinically significant portal hypertension in HIV/HCV coinfected patients: A cross-control study

    Biomedicine and Pharmacotherapy, Vol. 159

  3. Predictive plasma biomarkers of long-term increase in hepatic steatosis index after HCV eradication in HIV/HCV-coinfected patients

    Biomedicine and Pharmacotherapy, Vol. 164

2022

  1. Blood microbiome is associated with changes in portal hypertension after successful direct-acting antiviral therapy in patients with HCV-related cirrhosis

    The Journal of antimicrobial chemotherapy, Vol. 77, Núm. 3, pp. 719-726

  2. Metabolomic changes after DAAs therapy are related to the improvement of cirrhosis and inflammation in HIV/HCV-coinfected patients

    Biomedicine and Pharmacotherapy, Vol. 147

  3. Similar humoral immune responses against the SARS-CoV-2 spike protein in HIV and non-HIV individuals after COVID-19

    Journal of Infection

2021

  1. HCV Cure With Direct-Acting Antivirals Improves Liver and Immunological Markers in HIV/HCV-Coinfected Patients

    Frontiers in Immunology, Vol. 12

  2. HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients

    Journal of Biomedical Science, Vol. 28, Núm. 1

2020

  1. Plasma metabolomic fingerprint of advanced cirrhosis stages among HIV/HCV-coinfected and HCV-monoinfected patients

    Liver International, Vol. 40, Núm. 9, pp. 2215-2227

  2. Telomere length increase in HIV/HCV-coinfected patients with cirrhosis after HCV eradication with direct-acting antivirals

    Journal of Clinical Medicine, Vol. 9, Núm. 8, pp. 1-13

2019

  1. Genetic variants upstream of TNFAIP3 in the 6q23 region are associated with liver disease severity in HIV/HCV-coinfected patients: A cross-sectional study

    Infection, Genetics and Evolution, Vol. 67, pp. 112-120

2017

  1. ADAR1 polymorphisms are related to severity of liver fibrosis in HIV/HCV-coinfected patients

    Scientific Reports, Vol. 7, Núm. 1

2016

  1. Relationship of TRIM5 and TRIM22 polymorphisms with liver disease and HCV clearance after antiviral therapy in HIV/HCV coinfected patients

    Journal of Translational Medicine, Vol. 14, Núm. 1

  2. Short communication: CXCL12 rs1029153 polymorphism is associated with the sustained virological response in HIV/Hepatitis C virus-coinfected patients on Hepatitis C Virus therapy

    AIDS Research and Human Retroviruses, Vol. 32, Núm. 3, pp. 226-231

2015

  1. Single nucleotide polymorphisms of CXCL9-11 chemokines are associated with liver fibrosis in HIV/HCV-coinfected patients

    Journal of Acquired Immune Deficiency Syndromes, Vol. 68, Núm. 4, pp. 386-395

2014

  1. PPARγ2 Pro12Ala polymorphism is associated with sustained virological response in HIV/HCV-coinfected patients under HCV therapy

    Journal of Acquired Immune Deficiency Syndromes, Vol. 67, Núm. 2, pp. 113-119

  2. PPARγ2 Pro12Ala polymorphism was associated with favorable cardiometabolic risk profile in HIV/HCV coinfected patients: A cross-sectional study

    Journal of Translational Medicine, Vol. 12, Núm. 1